Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
Press releases published on August 7, 2025
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth …
White Hydrogen Takes the Spotlight as a New Clean Energy Powerhouse
GlobeNewswire
·
August 7, 2025
Boston, Aug. 07, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global White Hydrogen Market” is expected to reach $56.8 million by the end of 2030, growing at a CAGR of 7.1% for the forecast period of 2025-2030. This report …
The French NP Launches Wellness Program Targeting Healthy Aging on Boston’s South Shore
EIN Presswire
·
August 7, 2025
New initiative in Hingham, MA reframes mid-life as a second spring through evidence-based care for women and men HINGHAM, MA, UNITED STATES, August 7, 2025 /EINPresswire.com/ -- The French NP, a boutique aesthetics and regenerative health practice in …
SurgiBox Achieves CE Mark for SurgiField System Devices to Improve Access to Safe Surgery at the Point of Need
GlobeNewswire
·
August 7, 2025
CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- SurgiBox, a medical technology company committed to improving access to safe, clean surgery at the point of need, announced today it has received the CE Mark under MDR for the medical devices that …
Allergy Diagnostics and Treatments Market to Reach $96.4 Billion by 2030
GlobeNewswire
·
August 7, 2025
Boston, Aug. 07, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Markets for Allergy Diagnostics and Treatments” is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual …
Alkeus Pharmaceuticals Announces Presentation of Positive Interim TEASE-3 Study Data in Early-Stage Stargardt Disease Patients Treated with Oral Gildeuretinol
GlobeNewswire
·
August 7, 2025
Gildeuretinol acetate demonstrated less loss in ellipsoid zone (EZ) area compared to historical sibling controls. Early-stage Stargardt disease patients treated with gildeuretinol for two to seven years exhibited relatively stable disease over the course …
Employers pull back on pay increases despite rising inflation, Payscale Salary Budget Survey Finds
GlobeNewswire
·
August 7, 2025
After years of strong wage growth driven by a competitive labor market, U.S. employers are pulling back and planning for a 3.5% salary budget increase in 2026, down 0.1% from 2025, suggesting salary budgets are settling into a more sustainable pace after …
Paragonix LIVERguard System Shown to Reduce Post-Transplant Complications in Transplant Recipients
GlobeNewswire
·
August 7, 2025
WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, announced today the presentation of impactful clinical data on the use of its advanced organ preservation …
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meeting Expect initial data from Phase 2 study of DISC-0974 in patients with anemia of …
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter …
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 7, 2025
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset -- -- Completed follow-on …
MACOM Reports Fiscal Third Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
LOWELL, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal third quarter ended July 4, 2025. Third …
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities to advance pivotal development of …
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
GlobeNewswire
·
August 7, 2025
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain …
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
August 7, 2025
Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-end Expanding total enrollment of …
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 …
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 7, 2025
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed …
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part …
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
August 7, 2025
RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025 Phase 2 trial of RAP-219 in bipolar mania has been initiated and is enrolling patients; trial remains on track, …
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose …